Literature DB >> 10435083

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.

G Palù1, A Cavaggioni, P Calvi, E Franchin, M Pizzato, R Boschetto, C Parolin, M Chilosi, S Ferrini, A Zanusso, F Colombo.   

Abstract

Retrovirus-mediated gene therapy is a particularly attractive approach for glioblastoma multiforme (GBM), given the poor prognosis of this tumour and its localized proliferation in post-mitotic tissue. In this study we assessed, for the first time in humans, the therapeutic potential of a newly designed bicistronic Moloney vector (pLIL-2-TK), combining the expression of a suicide gene (thymidine kinase, tk) with an immunomodulatory gene (human interleukin 2, IL-2). Evidence of transgene activity in the treated tumours is presented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435083     DOI: 10.1038/sj.gt.3300805

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

Review 1.  Gene therapy for brain tumors.

Authors:  K Bansal; H H Engelhard
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  The importance of genetic services for the theory of health: a basis for an integrating view of health.

Authors:  Juan Manuel Torres
Journal:  Med Health Care Philos       Date:  2002

Review 3.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 4.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

Review 5.  Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis.

Authors:  Fei Zhao; Jinhui Tian; Lifeng An; Kehu Yang
Journal:  J Neurooncol       Date:  2014-04-23       Impact factor: 4.130

Review 6.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

Review 7.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

8.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 9.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

10.  Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

Authors:  Gwendalyn D King; Kurt M Kroeger; Catherine J Bresee; Marianela Candolfi; Chunyan Liu; Charlene M Manalo; A K M Ghulam Muhammad; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2008-02-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.